Intellia Therapeutics, Inc. (NTLA) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. Financial performance shows a decrease in cash and collaboration revenue, but there is effective cost management. Product development updates are positive, with brisk enrollment and strategic focus on high-value programs. However, the Q&A highlights uncertainties, such as vague responses about patient metrics and competitive pressures. The financial health is stable, and there is no significant guidance change. The market cap suggests a moderate reaction. Overall, these factors balance out, leading to a neutral sentiment prediction for the stock price.
Key Financial Performance
Cash, cash equivalents and marketable securities $707.1 million as of March 31, 2025, down from $861.7 million as of December 31, 2024, a decrease of $154.6 million. This reflects normal operational expenses and nonrecurring costs associated with portfolio prioritization and workforce reduction.
Collaboration revenue $16.6 million during Q1 2025, down from $28.9 million during Q1 2024, a decrease of $12.3 million. The decrease was mainly driven by a reduction in collaboration revenue under the AvenCell License and Collaboration Agreement, including a one-time recognition of revenue of approximately $21 million in Q1 2024.
R&D expenses $108.4 million during Q1 2025, down from $111.8 million during Q1 2024, a decrease of $3.4 million. The decrease was primarily due to lower employee-related expenses, stock-based compensation, and research materials, offset by increased spending on lead programs.
Stock-based compensation in R&D expenses $12.6 million for Q1 2025.
G&A expenses $29 million during Q1 2025, down from $31.1 million during Q1 2024, a decrease of $2.1 million. The decrease was primarily due to lower employee-related expenses from workforce reduction and lower stock-based compensation, partially offset by severance expenses.
Stock-based compensation in G&A expenses $9.2 million for Q1 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
NTLA-2002: Dosing the first patient in the Phase 3 study for hereditary angioedema (HAE) and presenting new data at the European Academy of Allergy and Clinical Immunology Congress.
nexiguran ziclumeran (nex-z): Dosing the first patient in the Phase 3 study for hereditary ATTR with polyneuropathy and receiving RMAT designation for the treatment of ATTR with cardiomyopathy.
Market Expansion: Enrollment in the global Phase 3 HAELO study for HAE is progressing rapidly, confirming high unmet need despite existing treatment options.
Market Positioning: Intellia is building commercial foundations to bring therapies to patients quickly, with a focus on evolving into a commercially-ready company.
Operational Efficiency: The company has reduced its real estate footprint and workforce, which diminishes medium and long-term capital needs.
Enrollment Efficiency: Enrollment for Phase 3 studies is ahead of projections, with over 90 sites actively enrolling for nex-z.
Regulatory Strategy: Intellia is closely monitoring the regulatory environment and has experienced no changes in interactions with the FDA.
Financial Strategy: The company maintains a solid balance sheet with approximately $707.1 million in cash, sufficient to fund operations into the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory Environment: Intellia is closely monitoring the regulatory environment due to leadership changes and developments at the FDA. Although there have been no tangible changes to interactions with the agency or timelines, the company remains vigilant about potential impacts on their programs.
Pending Pharmaceutical Tariffs: The company is monitoring potential implications of pending pharmaceutical tariffs, although they express confidence in their established manufacturing and distribution capabilities.
Financial Position: Intellia's cash, cash equivalents, and marketable securities decreased from $861.7 million to approximately $707.1 million, reflecting normal operational expenses and nonrecurring costs associated with portfolio prioritization and workforce reduction.
Collaboration Revenue: Collaboration revenue decreased from $28.9 million in Q1 2024 to $16.6 million in Q1 2025, primarily due to a decrease in revenue under the AvenCell License and Collaboration Agreement.
R&D and G&A Expenses: R&D expenses decreased from $111.8 million to $108.4 million, while G&A expenses decreased from $31.1 million to $29 million, indicating cost management efforts amid ongoing development.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Phase 3 Studies: Dosed the first patient in Phase 3 studies for HAE and hereditary ATTR with polyneuropathy.
Regulatory Designations: FDA granted RMAT designation for nex-z for ATTR with cardiomyopathy, following prior designations for ATTR with polyneuropathy and NTLA-2002 in HAE.
Commercial Foundations: Building critical commercial foundations to bring therapies to patients quickly, with a strengthened leadership team.
Clinical Updates: Expect multiple clinical updates throughout the year, including new data from ongoing studies.
Enrollment Progress: Enrollment in Phase 3 studies is ahead of projections, with over 90 sites actively enrolling.
Cash Position: Cash, cash equivalents, and marketable securities were approximately $707.1 million as of March 31, 2025.
Operating Expenses Guidance: Expect a year-over-year decline in GAAP operating expenses of between 5% and 10% for 2025.
Funding Guidance: Cash balance is sufficient to fund operating plans into the first half of 2027.
BLA Filing Timeline: On track to file the first BLA in 2026.
Enrollment Completion: Expect to complete enrollment for Phase 3 studies by the end of 2025.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Cash, cash equivalents and marketable securities: Approximately $707.1 million as of March 31, 2025.
Collaboration revenue: $16.6 million during the first quarter of 2025.
R&D expenses: $108.4 million during the first quarter of 2025.
G&A expenses: $29 million during the first quarter of 2025.
Expected cash balance sufficiency: Sufficient to fund operating plans into the first half of 2027.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you give your updated metrics regarding the patient baseline characteristics, including percentage of patients on baseline stabilizer and the silencer dropping rate?
A:We expect more than 50% of the patients to be on Tafamidis in the study. We are monitoring that and expect a percentage of patients to cross over to silencer over time.
Q:Could you give us a little more in terms of what we should expect in terms of cash burn in the next 12 to 24 months?
A:We estimate our average cash use over 2025 and 2026 will be about $95 million per quarter, which will fund our operating plans into the first half of 2027.
Q:Have you considered non-dilutive financing post-2027?
A:We are considering various options for capital raising, including collaborations and potential royalty transactions.
Q:Can you help us understand how should we be thinking about the launch dynamics for HAE?
A:We believe we can progress efficiently and bring the drug to many patients, learning from prior one-time therapies.
Q:What was your reaction to myeloma not lowering their price after label expansion?
A:We are paying attention to the TTR market and believe there is significant opportunity for us.
Q:Can you talk about the enrollment in the U.S. for the Phase 3 study?
A:Enrollment is brisk, and we are maintaining it despite the approval of Vutrisiran.
Q:Can you elaborate on the timeline for ATTR cardiomyopathy?
A:Enrollment is progressing well, and we expect to finish by the beginning of 2027.
Q:What are your expectations for the enrollment rate in the MAGNITUDE 2 study?
A:Enrollment will be brisk, and we expect to provide more details as we get closer.
Q:What are the dynamics if the events were to come in slower for the MAGNITUDE trial?
A:We have taken a conservative view on runway and funding, and our study design is not dictated by time.
Q:Review of Unclear Management Responses
A:Management avoided giving a direct answer regarding the specific rates of silencer dropping and the exact impact of Vutrisiran on enrollment, using vague language about monitoring and expectations without providing concrete data.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
ATTR amyloidosis
ATTR cardiomyopathy
Academy
Allergy Clinical
Chief Financial
Enrollment
FDA RMAT
Financial Officer
HAELO
Immunology Congress
Lebwohl
MAGNITUDE study
Patients milligram
Phase MAGNITUDE
Phase portion
Phase study
President Chief
RMAT designation
amyloidosis cardiomyopathy
balance sheet
burden HAE
cash
compensation
decrease
designation nex
environment change
lead program
nex ATTR
plan
progress
research need
study ATTR
study HAE
treatment ATTR
value
NTLA Transcript
Intellia Therapeutics, Inc. (NTLA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-12
Intellia Therapeutics, Inc. (NTLA) Q4 2025 Earnings Call Transcript
Unknown2-26
The earnings call revealed an increase in revenue but also a widening net loss due to higher R&D expenses. The cash reserves are decreasing, raising concerns about financial sustainability. The Q&A section did not provide clarity on management's responses, which may contribute to uncertainty. Despite a positive revenue growth, the financial health and lack of strategic updates suggest a negative sentiment, likely resulting in a stock price decline of -2% to -8%.
Intellia Therapeutics, Inc. (NTLA) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neutral1-14
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call highlights several concerns: unclear management responses to critical questions, ongoing clinical hold, and lack of precise financial guidance. Despite some positive aspects like reduced net loss and strategic financing options, the uncertainty surrounding safety events and potential regulatory challenges outweigh the positives. Given the company's market cap, the stock price is likely to experience a negative reaction in the short term.
NTLA Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
